 |
|
|
|
|
|
 Title: |
US5837252:
Nontoxic extract of Larrea tridentata and method of making same
[ Derwent Title ]
|
| Country: |
US United States of America
|
| |
| Inventor: |
Sinnott, Robert A.; Chandler, AZ
Clark, W. Dennis; Phoenix, AZ
DeBoer, Kenneth Frank; Belgrade, MT
|
| Assignee: |
Larreacorp, Ltd., Chandler, AZ
other patents from LARREACORP, LTD. (748144) (approx. 4)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
1998-11-17
/ 1996-10-07
|
| Application Number: |
US1996000726686
|
| IPC Code: |
Advanced:
A23L 1/30;
A61K 36/185;
A61K 36/28;
C07C 37/07;
Core:
C07C 37/00;
more...
IPC-7:
A01N 65/00;
|
| ECLA Code: |
C07C37/07; A23L1/30; A23L1/30B; A61K36/185+M;
|
| U.S. Class: |
Current:
424/737;
Original:
424/195.1;
|
| Field of Search: |
424/195.1
|
| Priority Number: |
| 1996-10-07 |
US1996000726686 |
| 1996-07-01 |
US1996000020946P |
|
| Abstract: |
A nontoxic, therapeutic agent having pharmacological activity comprising concentrated extract of Larrea tridentata plant material and ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol, or vitamin E is made by a process in which the plant material is extracted using an organic solvent, preferably acetone, and is then saturated with one of the listed reducing agents acid to reduce the toxic NDGA quinone, which naturally occurs in the plant material, to NDGA itself. Additional amounts of ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol, or vitamn E may be added to the extract to inhibit the natural oxidation of the NDGA into the toxic NDGA quinone in vivo, or during processing or storage. The resulting extract is useful in the treatment of viral diseases caused by viruses from the Herpesviridae family or viruses which require the Sp1 class of proteins to initiate viral replications. The resulting compound can also be used as an anti-inflammatory when the inflaatory diseases are mediated by the effects of leukotrienes. The listed reducing agents can also be used to stabilize NDGA as a therapeutic agent or a food additive.
|
| Attorney, Agent or Firm: |
Benson, David K. ;
Nichols, Steven L. ;
|
| Primary / Asst. Examiners: |
Witz, Jean C.; Hanley, Susan
|
| Maintenance Status: |
E2 Expired Check current status
|
| INPADOC Legal Status: |
Show legal status actions
Family Legal Status Report
|
| Designated Country: |
AL AM AT AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD
|
| Family: |
Show 18 known family members
|
First Claim:
Show all 8 claims |
What is claimed is:
1. A method of preparing a medicinally effective, nontoxic composition containing an extract of Larrea tridentata plant material produced by the steps of:
- harvesting pant material comprising leaves from Larrea tridentata shrubs;
- air drying said harvested plant material at ambient temperature and humidity for at least one week;
- maintaining said plant material in whole form without chopping, grinding or powdering;
- extracting said Larrea tridentata plant material in whole form by recirculating acetone over said plant material at least three times to produce a Larrea tridentata extract which comprises NDGA quinone;
- filtering particulate impurities from said extract;
- adding polysorbate 80 to said extract as an emulsifying and stabilizing agent, wherein 5 mL of polysorbate 80 are added per 50 L of extract;
- reducing said NDGA quinone in said extract to NDGA by passing said extract through a column packed with powdered ascorbic acid to produce a reduced extract, wherein 5 g of ascorbic acid powder are provided per liter of extract being reduced;
- concentrating said reduced extract by boiling off the acetone solvent at about 100°C. until the volume of said extract is reduced by 90% to produce a concentrated extract;
- adding additional amounts of ascorbic acid effective to prevent oxidation of said NDGA in said concentrated extract; and
- optionally, combining said concentrated extract with a pharmaceutically acceptable carriers, excipients and/or agents.
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
| Forward References: |
Show 8 U.S. patent(s) that reference this one
|
|
|
|
|
|
|
| Foreign References: |
None
|
| Other Abstract Info: |
CHEMABS 128(22)275069M
DERABS C1999-023379
DERABS C1998-261002
DERABS C1999-023379
DERABS C1999-539003
|
| Other References: |
Timmermann "Practical uses of Larrea,' in Creosote Bush: Biology and Chemistry of Larrea in the New World Deserts," Mabry et al. eds. (1977) (Dowden, Hutchison and Ross: Pennsylvania) pp. 252-276.
Tierra, L., "Chapparal," The Herbs of Life: Health and Healing Using Western and Chinese Techniques, pp. 561, 180-181 (1992).
Crellin, J.K. et al., "Chapparal," Herbal Medicines Past and Present II: A Reference Guide to Medicinal Plants, pp. 150-151 (1990).
Sakakibara, et al., Flavonoid Methyl Esters on the External Leaf Surface of Larrea Tridentata and L. Divaricata, 1976, pp. 727-731.
(5 pages)
Obermeyer, et al., Chemical Studies of Phytoestrogens and Related Compounds in Dietary Supplements: Flax and Chaparral, 1995, pp. 6-10 vol. 208.
(7 pages)
Cited by 5 patents
[ISI abstract]
Phytochemistry vol. 23(6) Donald MacRae, et al., Biological Activities of Lignans, 1984, pp. 1207-1220.
(14 pages)
Cited by 10 patents
Proc. Natl. Acad. Sci. USA vol. 92, Gnabre et al., Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans, 1995, pp. 11239-11243.
(5 pages)
Cited by 6 patents
[ISI abstract]
Gnabre et al., Characterization of Anti-HIV Lignans from Larrea tridentata, 1995, pp. 12203-12210, Tetrahedron vol. 51(4).
(8 pages)
Cited by 10 patents
[ISI abstract]
Gnabre et al., Isolation of anti-HIV-1 lignans from Larrea tridentata by counter-current chromatography, 1996, pp. 353-364 J. Chromatography vol. 719.
(12 pages)
Cited by 4 patents
[ISI abstract]
Amer. Soc. Hematol. vol. 88(2) Nador et al., Primary Effusion Lymphoma: A Distinct Clinicopathologic Entity Associated With the Kaposi's Sarcoma--Associated Herpes Virus, 1996, pp. 645-656.
(12 pages)
Cited by 4 patents
[ISI abstract]
The Philadelphia Inquirer Crenson, Kaposi's Sarcoma is tied to herpes, Jul. 31, 1996, p. A4.
Altman, Aids Cancer Said to Have Viral Source: Breakthrough Seen in Kaposi's Sarcoma, Feb. 1, 1995, p. A22 The New York Times.
Critchfield et al., Inhibition of HIV Activation in Latently Infected Cells by Flavonoid Compounds in AIDS Research and Human Retroviruses, 1996, pp. 39-46 vol. 12(1).
(8 pages)
Cited by 3 patents
[ISI abstract]
Amer. College Phys. vol. 121 Henderson, The Role of Leukotrienes in Inflammation, 1994, pp. 684-697.
(14 pages)
Cited by 12 patents
[ISI abstract]
Israel et al., Effect of Treatment With Zileuton, a 5-Lipoxygenase Inhibitor, in Patients With Asthma, 196, pp. 932-936 JAMA vol. 275(12).
Gordon, The Microbicical Potential of Various Creosotebush (Larrea Tridentata) Extracts, 1987, pp. 83-85 vol. 21, J. Arizona--Nevada Acad. Sci.
|
|
 Nominate this for the Gallery...
|
|
